Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromosome 17

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Chromosome 17. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-000208-34 Sponsor Protocol Number: CAMN107A2303 Start Date*: 2007-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr...
    Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017775-19 Sponsor Protocol Number: CAMN107EIC01 Start Date*: 2010-05-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
    Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005694-21 Sponsor Protocol Number: EWALL-PH-01 (Graalphag06) Start Date*: 2007-06-29
    Sponsor Name:CH-Versailles
    Full Title: AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHIL...
    Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000251-89 Sponsor Protocol Number: 1042-0800 Start Date*: 2014-10-22
    Sponsor Name:Antwerp University Hospital
    Full Title: A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome
    Medical condition: behavioral problems in children with fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002485-39 Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 Start Date*: 2019-06-14
    Sponsor Name:Ovid Therapeutics, Inc.
    Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP...
    Medical condition: developmental and epileptic encephalopathies
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-002476-92 Sponsor Protocol Number: 20120215 Start Date*: 2015-06-29
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio...
    Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-001539-31 Sponsor Protocol Number: FE999905 CS002 Start Date*: 2005-09-16
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X
    Medical condition: Zomacton is indicated for the long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turn...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-000678-27 Sponsor Protocol Number: CABL001J12301 Start Date*: 2021-08-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leuk...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) FI (Trial now transitioned) NL (Completed) DK (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022638-96 Sponsor Protocol Number: CAFQ056B2214 Start Date*: 2011-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021790-37 Sponsor Protocol Number: UK_S-H_08_0006 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck
    Full Title: Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)
    Medical condition: The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10056292 Androgen insensitivity syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000705-20 Sponsor Protocol Number: EsPhALL2017/COGAALL1631 Start Date*: 2017-12-11
    Sponsor Name:Università degli Studi Milano Bicocca
    Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
    Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003791-13 Sponsor Protocol Number: BP42992 Start Date*: 2022-01-11
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15...
    Medical condition: Dup15q Syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083952 Dup15q syndrome LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-023111-34 Sponsor Protocol Number: SG1/001/10 Start Date*: 2011-07-18
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.
    Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003667-11 Sponsor Protocol Number: M15-550 Start Date*: 2016-08-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019577-16 Sponsor Protocol Number: EGF114299 Start Date*: 2010-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-lin...
    Medical condition: HER2-positive metastatic breast cancer who have received prior trastuzumab and endocrine therapies
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) IE (Prematurely Ended) PL (Completed) BE (Completed) BG (Prematurely Ended) NO (Ongoing) GB (Completed) LT (Prematurely Ended) PT (Prematurely Ended) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001850-80 Sponsor Protocol Number: NLG-MCL8 Start Date*: 2021-04-07
    Sponsor Name:Skåne University Hospital
    Full Title: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma
    Medical condition: Mantle Cell Lymphoma (MCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001691-39 Sponsor Protocol Number: UKM17_0023 Start Date*: 2019-07-16
    Sponsor Name:University Hospital Münster
    Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
    Medical condition: Lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001286-20 Sponsor Protocol Number: CABL001I12201 Start Date*: 2021-07-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP...
    Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    21.0 100000004864 10060498 Juvenile chronic myeloid leukemia LLT
    24.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002260-33 Sponsor Protocol Number: CA180-226 Start Date*: 2009-02-16
    Sponsor Name:Bristol-Myers Squibb Internaltional Corporation
    Full Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised...
    Medical condition: Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA